Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the optimized AR antagonist compound 39 showed potent hair growth activity with improved safety in mice, suggesting potential for better topical treatments for androgenetic alopecia.

This study provides evidence that five Hyp-O-GALT genes are crucial for AGP galactosylation and that AGP glycans are vital for various aspects of plant growth and development.

In this study, baricitinib showed effectiveness and good tolerability in treating severe alopecia areata over 52 weeks.

This study observed that MAA beads improved vascularization in non-diabetic male mice by modulating the Shh signaling pathway in wound granulation tissue, but showed no such effects in females.

This study found that patients with alopecia areata had significantly higher systemic immune-inflammation index levels compared to healthy controls, regardless of the disease's severity.

Deoxyshikonin from Arnebiae Radix helps hair grow by activating a specific cell pathway.

This study suggests that macrophages, particularly CD206⁺ macrophages, play a crucial role in squaric acid dibutylester-induced hair growth in alopecia areata treatment.

This study investigated the sub-acute toxicity of Eclipta alba extract in Wistar albino rats, finding generally comparable hematological and biochemical parameters to controls, but noted mild morphological liver and kidney changes at the highest dose, highlighting a key area for further safety research.

This study found that CNGC 6, CNGC 9, and CNGC 14 are crucial for maintaining calcium oscillations necessary for normal root hair growth in plants, with mutations leading to defects like swelling and bursting.

This study observed that baricitinib treatment led to significant improvement in a patient's alopecia areata symptoms and suggests further clinical trials to explore its potential as a treatment.

This meta-analysis concluded that compound glycyrrhizin combined with conventional treatments enhanced hair regrowth in alopecia areata patients, though it was associated with some mild adverse effects like oedema.

This review discusses the condition alopecia areata and summarizes its available treatments, mentioning three recently approved Janus kinase inhibitors, but reports no new clinical results.

In this case study, a 29-year-old man with alopecia areata experienced satisfactory hair regrowth after five months of combined intralesional triamcinolone acetonide and platelet-rich plasma therapy.

The authors concluded that FDA-approved JAK inhibitors, shown to be safe and effective in phase 3 trials, are promising treatment options for severe alopecia areata.

In this study, the researchers observed significant metabolic dysregulation in central centrifugal cicatricial alopecia, particularly involving lipid metabolism and the downregulation of AMPK-related genes.

This paper introduces a hypothesis that elevated DHT at puberty may increase cerebral heat output, creating chronic thermal stress linked to androgenetic alopecia, and suggests this could be tested with MR thermometry.

This study found that certain plasma protein ratios, specifically AGRN/HSPG2 and DECR1/FKBP1B, were significantly associated with an increased risk of alopecia areata, indicating potential causal relationships but reverse causality was not supported.

This study presents case reports of four patients with alopecia areata or alopecia universalis, highlighting varied responses to treatments like prednisone, intralesional triamcinolone, and squaric acid dibutyl ester.

In this study, the researchers developed an optimal emulgel formulation for treating androgenic alopecia, determining that a base with 0.3% Carbomer Ultraz 10, 0.1% potassium sorbate, and 0.2% triethanolamine offered the best properties for drug release, application compliance, safety, and stability.

This study found that escalating baricitinib to 6 mg daily improved hair loss in 75% of patients with severe refractory alopecia areata who responded poorly to standard treatments, while also noting manageable short-term safety concerns under close monitoring.

This study suggests that potent topical corticosteroid occlusion may be a safe and effective treatment option for pediatric patients with severe alopecia areata, although further research is needed on its long-term safety and recurrence.

This study found that a composition including Serenoa repens extract and anti-inflammatory agents effectively suppressed inflammation-related gene expression in a keratinocyte model, suggesting a potential dual strategy for treating androgenetic alopecia.

This study used a multi-layer in silico framework to evaluate Korean herbal compounds for androgenetic alopecia, identifying Biochanin A, Saponin Re, and Emodin as potential topical candidates with distinct safety and affinity profiles, although these findings remain purely computational without experimental validation.

This study reports that the newly optimized AR antagonist 39 demonstrated effective hair growth and safety in a mouse model of androgenetic alopecia, showing comparable efficacy to pyrilutamide with faster response and favorable pharmacokinetics, due to innovative structural design and dual metabolic inactivation strategy.

In this study, researchers found that a scallop adhesive protein (Sbp9 Δ) forms strong adhesive coatings via disulfide-sticker strategies, which also promote hair regeneration in mouse models by activating Wnt signaling and enhancing angiogenesis, proving more effective than minoxidil for androgenetic alopecia.

In this phase I study, CT-707, a new ALK inhibitor, showed a 77% response rate among Chinese patients with advanced ALK-rearranged non-small cell lung cancer, suggesting clinical effectiveness despite some adverse events like diarrhea and liver enzyme elevation.

This study reported that ritlecitinib was generally well tolerated over 72 months in patients aged 12 and older with alopecia areata, with adverse events like headache and nasopharyngitis observed, and safety outcomes consistent with previous studies.

This study retrospectively evaluated the effectiveness of off-label baricitinib in children with severe alopecia areata and found that 50% achieved treatment goals, though psychological effects were noted and laboratory abnormalities occurred in 42.86% of patients.

This study found no significant differences in certain proinflammatory protein levels between patients with alopecia areata and healthy controls but noted a potential association between disease severity and increased atherosclerosis risk.